HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Robert E Martell Selected Research

mocetinostat

12/2011Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial.
11/2010The class-I HDAC inhibitor MGCD0103 induces apoptosis in Hodgkin lymphoma cell lines and synergizes with proteasome inhibitors by an HDAC6-independent mechanism.
8/2008Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia.
6/2008Evaluation of the pharmacodynamic effects of MGCD0103 from preclinical models to human using a novel HDAC enzyme assay.
4/2008Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Robert E Martell Research Topics

Disease

9Neoplasms (Cancer)
01/2020 - 03/2005
3Breast Neoplasms (Breast Cancer)
12/2021 - 01/2020
2Colorectal Neoplasms (Colorectal Cancer)
10/2016 - 10/2013
2Hodgkin Disease (Hodgkin's Disease)
12/2011 - 11/2010
2Lymphoma (Lymphomas)
11/2010 - 02/2008
1B-Cell Lymphoma (Lymphoma, B Cell)
10/2021
1Carcinogenesis
06/2012
1Necrosis
11/2010
1Thrombocytopenia (Thrombopenia)
11/2010
1Leukemia
08/2008
1Myelodysplastic Syndromes (Myelodysplastic Syndrome)
08/2008
1Carcinoma (Carcinomatosis)
06/2007
1Febrile Neutropenia
06/2007
1Sepsis (Septicemia)
06/2007
1Diarrhea
06/2007
1Leiomyosarcoma
06/2007
1Esophageal Neoplasms (Esophageal Cancer)
03/2005
1B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
07/2002
1Pain (Aches)
02/2002
1Renal Cell Carcinoma (Grawitz Tumor)
01/2002
1Melanoma (Melanoma, Malignant)
01/2002

Drug/Important Bio-Agent (IBA)

5mocetinostatIBA
12/2011 - 04/2008
4Hormones (Hormone)IBA
12/2021 - 06/2007
4Histone Deacetylase InhibitorsIBA
12/2011 - 01/2008
3Proteins (Proteins, Gene)FDA Link
10/2021 - 03/2005
3Metformin (Glucophage)FDA LinkGeneric
01/2020 - 10/2013
3Histones (Histone)IBA
06/2008 - 01/2008
2Pharmaceutical PreparationsIBA
12/2021 - 01/2013
2Biomarkers (Surrogate Marker)IBA
10/2021 - 10/2016
2Histone Deacetylases (Histone Deacetylase)IBA
10/2021 - 01/2008
2Paclitaxel (Taxol)FDA LinkGeneric
06/2007 - 03/2005
27- cyano- 2,3,4,5- tetrahydro- 1- (1H- imidazol- 4- ylmethyl)- 3- (phenylmethyl)- 4- (2- thienylsulfonyl)- 1H- 1,4- benzodiazepine (BMS 214662)IBA
06/2007 - 03/2005
1fimepinostatIBA
10/2021
1Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA
10/2021
1AMP-Activated Protein KinasesIBA
01/2020
1Aromatase InhibitorsIBA
01/2020
1Hypoglycemic Agents (Hypoglycemics)IBA
10/2016
1DNA (Deoxyribonucleic Acid)IBA
06/2012
1Proteasome InhibitorsIBA
11/2010
1EnzymesIBA
06/2008
1Cyclin-Dependent Kinases (cdk Proteins)IBA
02/2008
1N- (5- (((5- (1,1- dimethylethyl)- 2- oxazolyl)methyl)thio)- 2- thiazolyl)- 4- piperidinecarboxamideIBA
02/2008
1Antineoplastic Agents (Antineoplastics)IBA
01/2008
1benzamideIBA
01/2008
1Transaminases (Aminotransferases)IBA
06/2007
1TransferasesIBA
03/2005
1taxaneIBA
03/2005
1Carboplatin (JM8)FDA LinkGeneric
03/2005
1CreatinineIBA
07/2002
1fludarabineIBA
07/2002

Therapy/Procedure

6Therapeutics
12/2021 - 01/2002
1Drug Therapy (Chemotherapy)
01/2020
1Stem Cell Transplantation
12/2011
1Activities of Daily Living (ADL)
02/2002